Shareholder Information

Investor FAQs

Below are some frequently asked questions. For all other investor enquiries please contact We commit to answering investor enquiries within 48 hours.

Q1 What does Trajan do?

Trajan designs, manufactures and supplies a portfolio of products and services comprising precision consumable products, devices and solutions. These products and solutions are used in the analysis of biological, food, water and other environmental samples. Trajan has a pipeline of new technologies which includes micro-sampling devices, novel sample preparation chemistries and a portable modular analytical instrument system.

Q2 What are Trajan’s key products?

Trajan supplies a broad range of precise technical products and solutions to the analytical science sector, as well as having a range of new technologies in various stages of development. Key product categories include:

  • Separation science: a range of products that facilitate the chemical separation of components in a sample, playing a critical role in the overall performance of an analytical instrument. Product families include gas chromatography (GC) inlet liners, chromatography columns and microfluidic devices.
  • Analytical syringes: high-value, exacting devices and technologies used to aspirate and dispense minute volumes of liquid, either coupled to instrument robotics or for standalone use.
  • Precision fluidic systems (PFS): including precise and inert tubing constructs to facilitate control of sample flow within instrument platforms.
  • Polymer science: including septa materials and caps and a range of sample preparation chemistries.
  • Dispensing syringes: which are used to precisely deliver and mix liquids in biochemistry and clinical automation systems.
  • Pathology: microscope slides and coverslips.
  • Automation: a range of advanced robotic automation workflow solutions.
  • Microsampling: a family of device platforms including the hemaPEN® remote blood-sampling device.
  • Miniaturisation: A miniature modular liquid instrument separation system.

Q3 What is Trajan’s business model and how does it generate revenue?

Trajan derives revenue from the sale of products, devices and solutions to a customer portfolio that includes the large multi-national original equipment manufacturers (OEMs) in the industry, pharmaceutical, food and contract research organisation (CRO) laboratories and scientific distribution companies.

The Company has a specialised approach, focusing on targeted segments where an analytical product or component has the potential to significantly impact data quality.

Q4 Who uses Trajan’s products?

The ultimate end-users of Trajan’s products today are the laboratories performing testing for the food, beverage, environmental, biological, pharmaceutical and pathology industries.

Q5 How does Trajan develop its products?

Trajan’s research and development (R&D) begins with traditional in-house R&D. Trajan employs nearly 80 scientists and engineers. This is complemented by an array of strategic collaborations and alliances with industry and academia, while also accessing applicable government grant funding where available.

Q6 What differentiates Trajan’s products from other similar products?

Trajan products possess precision, reproducible quality and consistency which enables end-users to achieve high standards of analytical performance. Trajan deeply understands the end-user applications and collaborates closely with customers.

Q7 What is Trajan’s growth strategy?

The analytical science industry has historically had an underlying growth rate of circa 4-6% CAGR. By developing best practice product solutions in each area of specialisation, Trajan’s goal is to outpace that rate through market share gain.

Trajan achieves this through multiple development activities that continuously introduce extension and emerging technologies to the business, designed to underpin further growth. Trajan also has a track record of successful identification and integration of specialist capabilities via acquisition. The Company has made four acquisitions (Axel Semrau, Neoteryx LLC, LEAP PAL Parts and Consumables) and one strategic investment (Humankind Ventures Ltd) since listing on the Australian Securities Exchange in June 2021, which have all worked to expand its product, manufacturing, and geographic footprint.

Q8 What is Trajan’s dividend policy?

The payment of a dividend by Trajan is at the discretion of the Board and will depend upon a number of factors (many of which may be outside the control of Trajan and its Directors and management, and are not reliably predictable), including the general business environment, operating results, cash flows and financial condition of Trajan’s future funding requirements, capital management initiatives, taxation considerations, any contractual, legal or regulatory restrictions on the payment of dividends by Trajan, and any other factors the Directors may consider relevant.

While it is the aim of Trajan that, in the longer term, its financial performance and position will enable the payment of dividends, at the Prospectus Date, Trajan does not intend, nor expect to declare nor pay any dividends in the immediate foreseeable future, as Trajan’s focus will be to reinvest available funds in order to maximise its growth.

Q9 Where do I find out information about my shareholding?

Trajan’s share registry is managed by Computershare. To access information on your shareholding please visit the Investor Centre or contact 1300 850 505 (within AU) or +61 (03) 9415 4000 (outside AU).

Q10 What impact is COVID having on Trajan’s business?

The predominant impact of the 2020 COVID-19 pandemic on the analytical science sector was disruption to supply chains, for example, delays in product deliveries to end-users. There was also uneven demand for products and services due to regional specific shutdowns and lockdowns.

Today, laboratories have become increasingly accustomed to operating in this disrupted environment and have established protocols to allow continuity of operations. In many cases, laboratories perform essential services and even where operations recorded lower processing volumes, a backlog of samples to be analysed built up and is expected to contribute to continued demand growth.

The pandemic is not expected to have a long-term effect on the fundamental growth drivers in the analytical science market as many pharmaceutical and biopharma companies are focusing on new drug development to combat the pandemic, which may contribute to unexpected growth in the chromatography and mass spectrometry markets.

Shareholder Communications

Recent legislative changes to the Corporations Act 2001 effective 1 April 2022 means there are new options available to you as a securityholder as to how you elect to receive your communications. We will no longer send you physical meeting documents unless you request a copy to be mailed.

We encourage you to provide your email address so we can communicate with you electronically when securityholder notices become available online for such items as meeting documents, dividend statements and annual reports. You can make a standing election to receive some or all of your securityholder communications in physical or electronic form.

To review or update your current communication preference simply logon to our share registry’s website You will need your Securityholder Reference Number (SRN) or Holder Identification Number (HIN).

Investor Contact

If you can’t find what you’re looking for on our website we’re happy to answer any questions about our company and products. Please connect with us on